Onderzoeksleiding
Prof. Dr. J.H. Richardus
Introductie
Prof. Dr. Richardus is betrokken bij meerdere internationale onderzoeksprojecten op het gebied van lepra, deels nog lopend en deels afgerond. Deze projecten zijn in samenwerking met allerlei partners in binnen- en buitenland. Sinds 2012 vormen hierbij de researchprojecten in Bangladesh i.s.m. Prof. Geluk (LUMC) de belangrijkste samenwerking binnen Nederland.
Projecten Richardus (vanaf 2015):
- Monitoring the effect of prophylactic interventions in contacts of leprosy patients including field-application of a novel immune-diagnostic test in Bangladesh (INDIGO#2).
- Chemoprophylaxis for leprosy: comparing the effectiveness and feasibility of a skin camp intervention to a health centre based intervention. An implementation trial in Mozambique, Ethiopia and Tanzania (PEP4LEP).
- Stop the Transmission of Leprosy; Indonesia, India, Brazil, Bangladesh, Nepal (PEP++).
- Leprosy elimination investment case and mathematical modelling study.
- Identification of human susceptibility genes and pathogen-based transmission patterns for human and environmental sources of M. leprae in a leprosy endemic area in Bangladesh.
- Field evaluation of novel immunodiagnostic tools for early detection of leprosy in a BCG vaccination field trial amongst contacts of leprosy patients (INDIGO 1).
- Leprosy Post-Exposure Prophylaxis Evaluating Feasibility and Impact on Leprosy Incidence (LPEP).
- The combined effect of chemoprophylaxis with rifampicin and immuno-prophylaxis with BCG, in the prevention of leprosy in contacts: a randomized controlled trial. (MALTALEP).
- Application of immunodiagnostic tools for early detection of leprosy in the field (IDEAL).
- Treatment of Early Neuropathy in Leprosy. (TENLEP)
Meer informatie kunt u vinden in bijgaand document: Richardus JH, Tiwari A, Barth-Jaeggi T, Arif MA, Banstola NL, Baskota R, et al. Leprosy post-exposure prophylaxis with single-dose rifampicin (LPEP): an international feasibility programme. Lancet Glob Health. 2021;9(1):e81-e90.
Selectie van 10 meest belangrijke lepra publicaties:
1. Richardus JH, Tiwari A, Barth-Jaeggi T, Arif MA, Banstola NL, Baskota R, et al. Leprosy post-exposure prophylaxis with single-dose rifampicin (LPEP): an international feasibility programme. Lancet Glob Health. 2021;9(1):e81-e90.
2. Steinmann P, Reed SG, Mirza F, Hollingsworth TD, Richardus JH. Innovative tools and approaches to end the transmission of Mycobacterium leprae. Lancet Infect Dis. 2017;17(9):e298-e305.
3. Smith WC, van Brakel W, Gillis T, Saunderson P, Richardus JH. The missing millions: a threat to the elimination of leprosy. PLoS Negl Trop Dis. 2015;9(4):e0003658.
4. Blok DJ, de Vlas SJ, Fischer EA, Richardus JH. Mathematical modelling of leprosy and its control. Adv Parasitol. 2015;87:33-51.
5. Smith CS, Noordeen SK, Richardus JH, Sansarricq H, Cole ST, Soares RC, et al. A strategy to halt leprosy transmission. Lancet Infect Dis. 2014;14(2):96-8.
6. Feenstra SG, Nahar Q, Pahan D, Oskam L, Richardus JH. Recent food shortage is associated with leprosy disease in Bangladesh: a case-control study. PLoS Negl Trop Dis. 2011;5(5):e1029.
7. Schuring RP, Richardus JH, Pahan D, Oskam L. Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. Vaccine. 2009;27(50):7125-8.
8. Smith C, Richardus JH. Leprosy strategy is about control, not eradication. Lancet. 2008;371(9617):969-70.
9. Moet FJ, Pahan D, Oskam L, Richardus JH, Group CS. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ. 2008;336(7647):761-4.
10. Croft RP, Nicholls PG, Steyerberg EW, Richardus JH, Cairns W, Smith S. A clinical prediction rule for nerve-function impairment in leprosy patients. Lancet. 2000;355(9215):1603-6.